PR Information mentioning DNAPrint and M2GEN....
Tampa, FL (AP) - It's not piracy if both parties win.
That is the mentale of the future business venture between Merck & Co. and the H. Lee Moffitt Cancer Center, as they begin the long and arduous road of various local and federal funding for joint ventures in study and customization of pharmaceuticals and treatment procedures. The two organizations are calling the new pet project M2GEN and plan to not only offer a plethora of jobs to the local Tampa marketplace, but boast a 50,000 square foot complex to house what is to be believed will be the top analysis in the industry.
But who will feel the pinch in this fusion of two medical power-houses? Many companies work with both the H. Lee Moffitt Cancer Center and Merck & Co. in various side projects and research. The problem is that not all will feel the glory of victory in this venture. In fact, the real players from the various subsidiary organizations working with both corporation will inevitably be hired by M2GEN to continue their work, while the companies they hold the flag for now may be left out in the cold.
Richard Gabriel of DNAPrint Genomics is one who may settle for the pinch to get out of the financial hole his company has been digging for years. "Realistically, our company has offered some of the most ground-breaking research in genomic pharmo-study. We have enjoyed a working relationship with the H. Lee Moffitt Cancer Center for quite some time, and hold patents on the latest in genomic study. But the fact is that we are small troop that has acquired more debt than a company our size can handle. M2GEN is going to offer us a degree of relief, with the purchase of our patents and the acquisition of some of our finest researchers we have to offer. Our compensation will be enough to regroup and focus in on other projects we would like to be involved with in the future."
In the case of DNAPrint Genomics, the pinch is worth the reward. But Richard Gabriel's organization is one of many others that both companies have had ties to in the past, and are expecting to continue work with as they move towards the completion of the M2GEN Project...Unfortunately so are their stockholders.
If DNAPrint Genomics is any indication of how the smaller firms are to be handled by the merger, than it is looking bleak for the majority of side project companies hoping that this is the type of merger one they had been waiting on to take their company to the next level.
In the end Richard Gabriel may be the only one seeing the forest for the trees in a sense where his company continues to press on with new ventures seen in the horizon, and the shareholders losing nothing more than what they have always taken a hit on in the topsy-turvy world of penny-stocks.
Not all companies will be so lucky.
- A horrible...horrible....damn near EVIL April Fool's Joke, Indeed. Happy belated, folks...Hope no one jumped before they got to the bottom of the post!
AI
